As a core component of the upstream segment of the pharmaceutical industry chain, the development of the active pharmaceutical ingredient (API) industry is closely linked to the overall evolution of global and domestic pharmaceutical markets. Downstream applications of APIs are highly concentrated in the pharmaceutical manufacturing sector and primarily include the following areas:
Human Pharmaceuticals:
This is the primary application area for APIs, covering chemical drugs, biologics, and traditional Chinese medicine formulations. Among these, chemical drug formulations account for the highest proportion of API demand, spanning multiple therapeutic areas such as anti-infectives, anticancer agents, cardiovascular and cerebrovascular drugs, psychotropic drugs, and endocrine agents. Specifically, APIs such as antibiotics, vitamins, antipyretic and analgesic agents, and anticancer agents serve as the key foundation for the production of corresponding formulations.
Veterinary Pharmaceuticals:
Demand continues to grow steadily, primarily for the production of drugs related to animal anti-infectives, growth promoters, and health management.
Other Sectors:
These include cosmetic ingredients (such as hyaluronic acid) and food additives. Among these, the use of cosmetic ingredients is showing a significant growth trend.
01 Domestic Market: Strong Demand and Accelerating Innovation
According to disclosures from listed pharmaceutical companies, the global API market has maintained a compound annual growth rate (CAGR) of approximately 6.8% over the past five years and is expected to approach USD 250 billion by 2026.
As global API manufacturing capacity continues shifting toward the Asia-Pacific region, increasing incidences of infectious diseases, cardiovascular diseases, and other chronic conditions are expected to further drive market demand.
China is currently one of the world's largest API suppliers, accounting for roughly one-third of global production capacity. The industry remains dominated by bulk APIs, while capacities for specialty APIs are gradually expanding as numerous patented drugs lose exclusivity. Under increasingly stringent environmental regulations and ongoing supply-side reforms, the sector is transitioning toward higher-quality and more intensive development.
Meanwhile, China has become the world's second-largest pharmaceutical market. Based on financial reports released by listed companies, the domestic pharmaceutical market grew from approximately RMB 1.5 trillion in 2018 to RMB 1.6 trillion in 2024, with a compound annual growth rate of around 1.1%. By 2027, the market is projected to reach RMB 2.2 trillion.
Innovation activity remains robust. In 2024, China's Center for Drug Evaluation (CDE) accepted 19,563 registration applications, including 2,087 applications for chemical APIs, representing a year-on-year increase of 30.03%.
Strong market demand combined with active innovation demonstrates the long-term resilience, sustainability, and competitiveness of China's API industry in the global marketplace.
02 Multiple Drivers Supporting Continued Industry Growth
Changes in Demographics and Healthcare Demand
Growing health awareness worldwide, particularly regarding chronic diseases, cancer, and age-related illnesses, is driving demand for related pharmaceutical products and APIs.
In addition, the global aging population is generating sustained demand for cardiovascular, anti-infective, and endocrine therapies, directly supporting growth in the API sector.
Expansion of the Generic Drug Market
The expiration of numerous blockbuster drug patents worldwide is accelerating generic drug development. As the essential raw materials for generic medicines, specialty APIs are entering a period of strong demand growth.
Government initiatives such as China's volume-based procurement program and policies supporting generic drug adoption in the United States are further expanding market opportunities for API manufacturers.
Growth of Emerging Markets
Healthcare systems across Southeast Asia, Latin America, Africa, and other emerging regions continue to improve, leading to rapid expansion of local pharmaceutical markets.
Since domestic pharmaceutical manufacturing capabilities in many of these regions remain limited, demand for imported APIs continues to rise, creating significant export opportunities for major API-producing countries.
Global Industry Restructuring
Rising environmental compliance costs and production expenses in Europe and North America are accelerating the relocation of API manufacturing to Asia-Pacific countries such as China and India.
Benefiting from cost advantages, comprehensive supply chains, and continuous technological upgrading, Asia has become the primary destination for global capacity transfers.
Technological Innovation and Business Model Upgrades
The adoption of green chemistry, biocatalysis, and biosynthesis technologies is improving manufacturing efficiency while reducing environmental impact.
Meanwhile, integrated business models such as "API + CXO" and "API + Finished Dosage Forms" are enhancing profitability and strengthening risk resistance among leading enterprises.
Policy and Regulatory Support
Governments worldwide continue to encourage pharmaceutical innovation and sustainable manufacturing through supportive policies.
China has placed increasing emphasis on pharmaceutical supply chain security and self-sufficiency while continuously improving environmental and quality standards, promoting industry optimization and standardized development.
03 Future Trends: Higher Value and Greater Efficiency
Expansion into High-Value Segments
Patented APIs and biopharmaceutical APIs offer significantly higher profit margins and stronger growth potential.
As Chinese manufacturers continue improving R&D capabilities and obtaining international regulatory certifications such as FDA DMF filings and EU CEP certifications, they are expected to secure a larger share of the global high-value API market.
At the same time, synergies between API manufacturing and CDMO services will further expand growth opportunities.
Supply Chain Integration and Global Expansion
Leading API companies are increasingly extending upstream to secure critical raw material supplies while expanding downstream into finished formulations and CDMO services.
This integrated approach enhances cost control, strengthens profitability, and improves competitiveness.
Establishing overseas manufacturing facilities and R&D centers also enables companies to stay closer to end markets, mitigate trade barriers, and strengthen their global presence.
Continued Industry Consolidation
API manufacturing requires significant investment in environmental protection and compliance systems. Tightening environmental regulations worldwide, combined with rising raw material and labor costs, are increasing operational pressures.
Many smaller companies lacking sufficient resources for environmental upgrades and innovation investment may gradually exit the market.
In contrast, leading enterprises with advantages in technology, scale, regulatory compliance, and integrated supply chains are expected to further strengthen their market positions, driving continued industry consolidation.
Conclusion
The global API industry is entering a new stage characterized by innovation, sustainability, and globalization. Supported by expanding healthcare demand, technological advancement, policy incentives, and evolving international supply chains, China's API sector remains well positioned for long-term growth.
Going forward, companies that focus on technological innovation, regulatory compliance, green manufacturing, integrated business models, and global market expansion will be best positioned to capture opportunities and strengthen their competitive advantages in the evolving pharmaceutical landscape.
